Recent Press Releases

December 8, 2000	Myriad Genetics Acquires Exclusive Rights to Cancer Drug in Phase II Human Clinical Trials
December 8, 2000	Encore Pharmaceuticals Lincenses Lead Cancer Compound to Myriad Genetics
April 10, 2000	Encore Updates Clinical Development of E-7869 in Cancer
April 17, 2000	Encore Reports on Clinical Development Progress with Their Lead Drug Candidate E-7869
April 15, 1999	Encore Pharmaceuticals Begins Phase IIa Clinical Trial in Prostate Cancer Patients